TRLV Stock Forecast & Price Target

Trulieve Cannabis is positioned favorably because its dominant Florida franchise, 206 DEA-registered dispensaries, and 3.5M sq. ft. of cultivation capacity create a scaled, vertically integrated platform that now benefits from Schedule III rescheduling and the relief from 280E tax pressure. Growth is being broadened by regulatory expansion in Georgia and Pennsylvania, with 3Q26 revenue guided at $222M, record-like customer engagement supported by 1.1M+ rewards members, and a pharmacy pipeline that could materially extend wholesale distribution. The outlook is further strengthened by optionality in Texas, where final license approval could open access to a market management believes may ultimately rival Trulieve’s existing operations, while the 11/12/26 Hemp ban and 2026 federal catalysts could shift demand into regulated channels.

Trulieve Cannabis is pressured by a highly fragmented state-by-state regulatory backdrop that leaves licensing, product availability, and tax structures uncertain, while delayed approvals for expansion such as Texas or broader rescheduling could slow growth and undermine the value of future opportunities. Its core exposure to Florida creates meaningful seasonality, since 3Q sales typically weaken as snowbirds leave during warmer months, and its concentration in mature markets like Florida and Arizona heightens competitive and pricing pressure. Even with a leading retail position, slower-than-expected market expansion, restrictive programs in states like West Virginia and Alabama, and the loss of potential Pennsylvania adult-use tax revenue support a cautious fundamental outlook.